Earlier intervention in the management of hypercholesterolemia: what are we waiting for?

The thesis advanced here is that we are initiating treatment of hypercholesterolemia (and other risk factors) too late in life. Initiating treatment at, for example, age 30 years instead of age 60 years might very well prevent not just 30% of events, as in the 5-year statin trials, but perhaps as many as 60%.